Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.35 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21398891 | 0.88 | MAPT (0.32) | — | |
| SCHEMBL24867055 | 0.88 | MAPT (0.32) | — | |
| SCHEMBL21399193 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24866477 | 0.77 | KDM4E (0.42) | — | |
| SCHEMBL21398887 | 0.76 | KDM4E (0.44) | — | |
| SCHEMBL21399022 | 0.75 | MAPT (0.34) | — | |
| SCHEMBL21399105 | 0.73 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA7BPTFCHRNB4 | |
| SCHEMBL21398930 | 0.72 | SPR (0.33) | — | |
| SCHEMBL21399055 | 0.70 | ALDH1A1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21380776 | 0.69 | BPTF (0.38) | CHRNB2CHRNA4CHRNA7BPTFCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019182960-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNA7 4798/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNA7 4798/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | CHRNB2 4738/4885CHRNA4 4859/4885CHRNA7 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.